Genetic evolution of T-cell resistance in the course of melanoma progression
Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 7, 2014
|
| In: |
Clinical cancer research
Year: 2014, Jahrgang: 20, Heft: 24, Pages: 6593-6604 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-14-0567 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-14-0567 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/20/24/6593 
|
| Verfasserangaben: | Antje Sucker, Fang Zhao, Birgit Real, Christina Heeke, Nicola Bielefeld, Stefan Maβen, Susanne Horn, Iris Moll, Raffaela Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, and Annette Paschen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1738049515 | ||
| 003 | DE-627 | ||
| 005 | 20230426130458.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201106s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-14-0567 |2 doi | |
| 035 | |a (DE-627)1738049515 | ||
| 035 | |a (DE-599)KXP1738049515 | ||
| 035 | |a (OCoLC)1341375569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sucker, Antje |e VerfasserIn |0 (DE-588)1161138153 |0 (DE-627)1024540596 |0 (DE-576)506375412 |4 aut | |
| 245 | 1 | 0 | |a Genetic evolution of T-cell resistance in the course of melanoma progression |c Antje Sucker, Fang Zhao, Birgit Real, Christina Heeke, Nicola Bielefeld, Stefan Maβen, Susanne Horn, Iris Moll, Raffaela Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, and Annette Paschen |
| 264 | 1 | |c October 7, 2014 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.11.2020 | ||
| 520 | |a Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. - Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell-stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alterations affecting the tumor-T-cell interaction. - Results: Metastases Ma-Mel-48a and Ma-Mel-48b, in contrast with Ma-Mel-48c, were infiltrated by T cells. The T-cell-stimulatory capacity was found to be strong for Ma-Mel-48a, lower for Ma-Mel-48b, and completely abrogated for Ma-Mel-48c cells. The latter proved to be HLA class I-negative due to an inactivating mutation in one allele of the beta-2-microglobulin (B2M) gene and concomitant loss of the other allele by a deletion on chromosome 15q. The same deletion was already present in Ma-Mel-48a and Ma-Mel-48b cells, pointing to an early acquired genetic event predisposing to development of β2m deficiency. Notably, the same chronology of genetic alterations was also observed in a second β2m-deficient melanoma model. - Conclusion: Our study reveals a progressive loss in melanoma immunogenicity during the course of metastatic disease. The genetic evolvement of T-cell resistance suggests screening tumors for genetic alterations affecting immunogenicity could be clinically relevant in terms of predicting patient responses to T-cell-based immunotherapy. Clin Cancer Res; 20(24); 6593-604. ©2014 AACR. | ||
| 700 | 1 | |a Kloor, Matthias |d 1972- |e VerfasserIn |0 (DE-588)124552803 |0 (DE-627)363416609 |0 (DE-576)294228616 |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 20(2014), 24, Seite 6593-6604 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Genetic evolution of T-cell resistance in the course of melanoma progression |
| 773 | 1 | 8 | |g volume:20 |g year:2014 |g number:24 |g pages:6593-6604 |g extent:13 |a Genetic evolution of T-cell resistance in the course of melanoma progression |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-14-0567 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/20/24/6593 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201106 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 16 | ||
| 998 | |g 124552803 |a Kloor, Matthias |m 124552803:Kloor, Matthias |d 910000 |d 912000 |d 50000 |e 910000PK124552803 |e 912000PK124552803 |e 50000PK124552803 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 14 | ||
| 999 | |a KXP-PPN1738049515 |e 3793132714 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"origin":[{"dateIssuedDisp":"October 7, 2014","dateIssuedKey":"2014"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Antje Sucker, Fang Zhao, Birgit Real, Christina Heeke, Nicola Bielefeld, Stefan Maβen, Susanne Horn, Iris Moll, Raffaela Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, and Annette Paschen"]},"person":[{"roleDisplay":"VerfasserIn","family":"Sucker","display":"Sucker, Antje","role":"aut","given":"Antje"},{"given":"Matthias","role":"aut","display":"Kloor, Matthias","family":"Kloor","roleDisplay":"VerfasserIn"},{"family":"Schadendorf","roleDisplay":"VerfasserIn","given":"Dirk","role":"aut","display":"Schadendorf, Dirk"}],"physDesc":[{"extent":"13 S."}],"relHost":[{"recId":"325489971","corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Association for Cancer Research"}],"pubHistory":["1.1995 -"],"disp":"Genetic evolution of T-cell resistance in the course of melanoma progressionClinical cancer research","note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"id":{"issn":["1557-3265"],"eki":["325489971"],"zdb":["2036787-9"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1995","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedDisp":"1995-","publisher":"AACR"}],"part":{"issue":"24","volume":"20","text":"20(2014), 24, Seite 6593-6604","pages":"6593-6604","year":"2014","extent":"13"},"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Association for Cancer Research"]}}],"id":{"eki":["1738049515"],"doi":["10.1158/1078-0432.CCR-14-0567"]},"title":[{"title_sort":"Genetic evolution of T-cell resistance in the course of melanoma progression","title":"Genetic evolution of T-cell resistance in the course of melanoma progression"}],"recId":"1738049515","note":["Gesehen am 06.11.2020"]} | ||
| SRT | |a SUCKERANTJGENETICEVO7201 | ||